Role of molybdenum-containing enzymes in the biotransformation of the novel ghrelin receptor inverse agonist PF-5190457: A reverse translational bed-to-bench approachs
Document Type
Article
Date of Original Version
1-1-2019
Abstract
(R)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)-1-(2-(5-(6-methylpyrimidin- 4-yl)-2,3-dihydro-1H-inden-1-yl)-2,7-diazaspiro[3.5]nonan-7-yl)ethan- 1-one (PF-5190457) was identified as a potent and selective inverse agonist of the ghrelin receptor [growth hormone secretagogue receptor 1a (GHS-R1a)]. The present translational bed-to-bench work characterizes the biotransformation of this compound in vivo and then further explores in vitro metabolism in fractions of human liver and primary hepatocytes. Following oral administration of PF-5190457 in a phase 1b clinical study, hydroxyl metabolites of the compound were observed, including one that had not been observed in previously performed human liver microsomal incubations. PF-6870961 or (R)-1-(2-(5-(2-hydroxy-6-methylpyrimidin- 4-yl)-2,3-dihydro-1H-inden-1-yl)-2,7-diazaspiro[3.5]nonan-7-yl)-2- (2-methylimidazo[2,1-b]thiazol-6-yl)ethan-1-one was biosynthesized using liver cytosol, and the site of hydroxylation was shown to be on the pyrimidine using nuclear magnetic resonance spectroscopy. The aldehyde oxidase (AO) inhibitor raloxifene and the xanthine oxidase inhibitor febuxostat inhibited the formation of PF-6870961 in human liver cytosol, suggesting both enzymes were involved in the metabolism of the drug. However, greater inhibition was observed with raloxifene, indicating AO is a dominant enzyme in the biotransformation. The intrinsic clearance of the drug in human liver cytosol was estimated to be 0.002 ml/min per milligram protein. This study provides important novel information at three levels: 1) it provides additional new information on the recently developed novel compound PF-5190457, the first GHS-R1a blocker that has moved to development in humans; 2) it provides an example of a reverse translational approach where a discovery in humans was brought back, validated, and further investigated at the bench level; and 3) it demonstrates the importance of considering the molybdenumcontaining oxidases during the development of new drug entities. SIGNIFICANCE STATEMENT PF-5190457 is a novel ghrelin receptor inverse agonist that is currently undergoing clinical development for treatment of alcohol use disorder. PF-6870961, a major hydroxyl metabolite of the compound, was observed in human plasma, but was absent in human liver microsomal incubations. PF-6870961 was biosynthesized using liver cytosol, and the site of hydroxylation on the pyrimidine ring was characterized. Inhibitors of aldehyde oxidase and xanthine oxidase inhibited the formation of PF-6870961 in human liver cytosol, suggesting both enzymes were involved in the metabolism of the drug. This information is important for patient selection in subsequent clinical studies.
Publication Title, e.g., Journal
Drug Metabolism and Disposition
Volume
47
Issue
8
Citation/Publisher Attribution
Adusumalli, Sravani, Rohitash Jamwal, R. S. Obach, Tim F. Ryder, Lorenzo Leggio, and Fatemeh Akhlaghi. "Role of molybdenum-containing enzymes in the biotransformation of the novel ghrelin receptor inverse agonist PF-5190457: A reverse translational bed-to-bench approachs." Drug Metabolism and Disposition 47, 8 (2019). doi: 10.1124/dmd.119.087015.